autologous immunoglobulin idiotype-KLH conjugate vaccine + sargramostim

This combination product consists of a **personalized conjugate vaccine** in which an **autologous immunoglobulin idiotype (Id)**—derived from a patient’s own tumor B-cells—is chemically linked to the carrier protein **keyhole limpet hemocyanin (KLH)** and then administered together with **sargramostim (GM-CSF)** as an adjuvant. The vaccine is designed to stimulate a patient-specific immune response against malignant B-cells by targeting the unique idiotype expressed by the tumor. KLH acts as a carrier and immunogenic stimulus, while sargramostim recruits dendritic cells and enhances antigen presentation. The product is used as an individualized immunotherapy primarily for follicular lymphoma and multiple myeloma, where the manufacturing process involves isolating the tumor immunoglobulin idiotype from the patient, synthesizing the KLH conjugate, and co-administering with GM-CSF. Mechanistically, the vaccine induces humoral and cellular anti-tumor responses, while GM-CSF boosts local dendritic cell recruitment and antigen processing. This approach has been studied in several clinical trials, with evidence of improved disease-free survival and idiotype-specific immune responses in some subgroups. Manufacturing has utilized hybridoma or recombinant (including plant-based) approaches to generate the idiotype-KLH conjugate[2][3][4].

Other names

autologous idiotype vaccine + sargramostimId-KLH vaccine + GM-CSFidiotype vaccine with keyhole limpet hemocyanin and sargramostim